During the past 8 years we have had some success in culturmg multiple myeloma as colonies (MY-CFUc) in vitro from human bone marrow aspirates (Millar et al., 1988) . Although MY-CFUc can be cultured from approximately 70% of patients at some time during treatment, in remission and/or at relapse the likelihood of growing the tumour in vitro is dependent on the individual patient and cannot be predicted from the level of bone marrow infiltration with plasma cells (Bell et al., 1990; Maitland et al., 1990) . Furthermore, the growth of MY-CFUc is not necessarily associated with progressive or fulminating disease (Bell et al., 1990; Maitland et al., 1990) . Since there are a number of patients from whom it has not been possible to grow MY-CFUc in vitro at any stage of disease, there is clearly scope for refining the culture procedure or determining whether there are specific genetic mutations in some myeloma cell populations which facilitate tumour cell proliferation in vitro in the absence of added growth factors. However, the significance of such mutations will only be of clinical value if their presence is associated not only with proliferative activity in vitro but also with prognosis.
Although multiple myeloma is charactensed by the presence of excess plasma cells in the bone marrow, the identification of circulating isotypic lymphocytes (RuizArguelles et al., 1984) , as well as the production of colonies in vitro consisting of cells which are lymphoplasmacytoid (Millar et al., 1988) , suggests that the major proliferative compartment occurs in less differentiated B cells. Also, the increased clonogenicity in vitro following cytotoxic chemotherapy, despite a decrease in tumour burden, suggests that multiple myeloma may be regulated by a homeostatic control mechanism in vivo (Maitland et al., 1990) . Furthermore, the failure to increase MY-CFUc formation in vitro by the addition of cyclophosphamide or verapamil to the VAMP regime (vincristine. adriamycin and methylprednisolone) suggests that the potential increase in tumour proliferative capacity after chemotherapy is dependent on the nature of the cytotox.ic insult (Bell et al., 1990) .
The concept that previous chemotherapy might influence subsequent attempts to culture myeloma cells in vitro is likely to produce constraints in addition to the possible requirement for added growth factors which may be required to stimulate cell division. Mobilisation of putative precursors which have evaded chemotherapy may be a prerequisite for the successful culture of MY-CFUc in vitro in some instances. Thus, in attempting to assess the relationship between colony formation in vitro with genetic mutations, the likelihood of a particular mutation effecting proliferation may be influenced by the drugs to which the patient has been subjected.
All eukaryotic organisms use GTP-binding proteins to control cellular processes which are involved in the transduction of signals initiated by growth factors and lymphokines. ras is a family of highly sequence-conserved proteins which have functional similarities with other GTP-binding proteins. In the human genome, three ras genes have been identified: H-ras-l, K-ras-2 and N-ras (Ellis et al., 1981; Parada et al., 1982; Hall et al., 1983) . A similar mechanism has been proposed for all GTP-binding proteins by which they exist in two interconvertible forms. When bound to GDP they are inactive, whereas they become functionally active when bound to GTP. In addition, they can recycle from GDP to GTP through intrinsic GTPase activity. Since activated versions of ras, in which mutations have led to the constitutive production of the GTP-binding form, have been found in many human solid tumours, including melanomas, teratocarcinomas, neuroblastomas and gliomas (for review see Barbacid, 1986) , it has been suggested that the abnormal growth of some cancers is due to the continuous activation of the signalling cascade initiated by the aberrant protein.
The role of mutated ras in haematological malignancies remains controversial. In multiple myeloma, mutations have been found in N-ras and K-ras, particularly at codon 61 in N-ras, with frequencies ranging from 12% to 47% of the patient populations studied (Paquette et al., 1990; Matozaki et al., 1991; Portier et al., 1992; Tanaka et al., 1992) . In a study by Neri et al. (1989) mutations in N-ras occurred in only a fraction of the neoplastic clone, suggesting that they may result from either the selective loss or the selective acquisition of mutated alleles during tumour development. In two other studies mutations in K-and N-ras occurred with greater frequency in patients with fulminating disease (67%) than in patients with less aggressive disease (27%) (Portier et al., 1992; Corradini et al., 1993) suggesting that the development of mutated ras alleles occurs in late or terminal stage multiple myeloma. In none of these studies did the authors attempt to culture cells which had mutated ras alleles in vitro.
Mutated H-ras has not been detected in clinical samples of myeloma, although high levels of H-ras protein (p21) correlate with poor prognosis (Tsuchiya et al., 1988) . Also, the greater expression of H-ras p21 in plasma cells from patients with multiple myeloma rather than monoclonal gammopathy of undetermined significance (MGUS) suggests that the overexpression of H-ras proto-oncogene may be involved in the transformation of the malignant plasma cell (Danova et al., 1990) .
The data presented represent a retrospective study of a group of patients with multiple myeloma from whom mononuclear cells were available which had been cryopreserved from the same sample that was used for MY-CFUc. The aim of the study was to determine whether patients from whom MY-CFUc were cultured in vitro had a poorer prognosis than those from whom cells did not proliferate in vitro and whether colony formation in vitro was associated with detectable levels of mutated N-or K-ras in the mononuclear cell fraction.
Materials and nwthods
Clinical samples Patients were recruited at random as they presented or were undergoing treatment for multiple myeloma. All patients had given written consent, following the Royal Marsden Hospital's Ethics Committee approval, to take part in laboratory-based studies. The criterion for entering the study was that sufficient mononuclear cells (MNCs) were available from the same bone marrow aspirate, or one taken within 2 months of that used for colony growth, for isolation of DNA for experiments involving the polymerase chain reaction (PCR). Among these 13 patients from whom sequential samples were taken for PCR studies no further treatment had occurred during the intervening period. There had been no changes in haematological or clinical parameters during the intervening period in these patients. Samples were accrued during the period from September 1987 to March 1993 and aliquots frozen as pellets in liquid nitrogen. The proliferation of myeloma cells as colonies (MY-CFUc) was examined at the time of bone marrow biopsy.
Bone marrow was aspirated from the posterior iliac crest under local anaesthesia and heparinised as described previously (Millar et al., 1988 Durie and Salmon (1981) .
Cell culture Asynchronous cultures of RPMI-8226 and HL60 cell lines were propagated by methods described previously (Millar et al., 1988) . Mononuclear cells were separated over FicollHypaque (Boyum, 1968) and assayed for myeloma colonies (MY-CFUc). Details of the methods have been reported previously (Millar et al., 1988) . Briefly, MY-CFUc were assayed by plating 1 x 10' MNCs per plate using heavily irradiated HL60 cells as an inhibiting layer to prevent the proliferation of granulocyte-macrophage colonies (GMCFUc) (Montes Borinaga et al., 1990) . Samples of MNCs were also plated in the absence of an HL60 underlay. Overlays containing MNCs were added to underlays in either 0.5 ml of a-medium supplemented with 20% fetal calf serum and 0.2% agar (final concentration) (agar/agar) or in 0.2 ml of medium without agar (agar/liquid). All Slot blotting for ras mutations ras mutations were analysed using the human ras Muta-lyser probe panels for K-ras codons 12, 13 and 61 and for N-ras codons 12, 13 and 61. The protocol for this was done according to the manufacturer's instructions (Clontech Labs., Cambridge Bioscewnce, UK). Probes were end-labellW with [y-3PJATP, as directed, using T4 polynucleotide kinase.
To determine the sensitivity of the assay, DNA from RPMI-8226 cells was mixed with placental DNA in known amounts and subjected to PCR. The products were analysed by Southern blotting.
Direct sequencing of PCR products K-ras exon I and exon 2 Aliquots of 50 id1 of PCR products were run on a 2% low melting point agarose gel (Ultrapure or Nuseive, Gibco BRL, UK) for 1.5-2h at 140V. The appropriate band was cut out from the gel and purified using (Figure 2 ). This sensitivity is similar to that noted by Farr et al. (1988) using the HT 1080 cell line, which is heterozygous for N61 lysine. In HL60 cells other workers (Bos et al., 1984) (Paquette et al., 1990; Matozaki et al., 1991; Portier et al.. 1992; Tanaka et al., 1992) , PCR products from all samples in which background activity had been detected by hybridisation and slot blotting were subjected to direct sequencing. From the total of 288 slot blots, 18 samples were sequenced for N-ras exon 2. 13 for N-ras dfor N-ras exon 2. aDead. bAlive at July 1994.
exon 1 and five for K-ras exon 2. The samples which were directly sequenced from patients whose mononuclear cells had produced MY-CFUc in vitro are identified in Table III . Wild-type alleles were found in all samples examined by direct sequencing, but there were no mutated alleles. The survival of patients used in this study is shown in Table IV . Among patients who are alive and from whom MY-CFUc were grown in vitro at the times when tests were done for mutated N-or K-ras alleles, four have had no further treatment. They remain in remission 62 (patient 10), 73 (patient 5), 74 (patient 6) and 75 months (patient 12) after sampling. Six of the remaining patients received intensive therapy with high-dose melphalan within 7 months after samples were used in these studies, and one patient received intensive therapy with busulphan 13 months after the samples were taken. Two of these seven patients now have progressive disease 16 months and 73 months after samples had been used for studies to detect mutated ras alleles. Subsequent bone marrow aspirates from 19/24 of these patients have produced myeloma colonies in vitro, including nine patients who remain alive.
Among patients whose cells did not produce MY-CFUc in vitro, ten remain alive, including the two patients with Waldenstrom's macroglobulinaemia. In this group of patients only one has had intensive therapy with high-dose melphalan since the samples were used in vitro. Tumour cells from four of these patients have subsequently produced myeloma colonies in vitro since this study, of whom one patient remains alive.
Discussion
We have explored the possibility that patients from whom MY-CFUc can be cultured have a poorer prognosis than those whose tumour does not proliferate in vitro. We have also investigated whether the detection of mutations in Nand K-ras at exons I and 2 in bone marrow aspirates was associated with our ability to grow MY-CFUc in vitro from the same samples or one taken within 2 months of that assessed for colony formation. Studies to detect activated oncogenes or quantitate the expression of specific protooncogenes in multiple myeloma may provide information about the pathogenesis of the disease and may provide targets for new treatment strategies if they are associated with poor prognosis. Despite the low levels of plasma cells in eight samples, MY-CFUc were grown from 24 samples from 45 patients, including those that had infiltration with plasma cells of 5% or less, and included four patients who were in complete response at the time of testing. We have previously shown that in patients who respond to induction chemotherapy with VAMP the residual myeloma cell population has enhanced proliferative activity in vitro, suggesting that tumour growth is regulated by a homeostatic control mechanism(s) (Maitland et al., 1990 ) which may be modulated by specific treatment regimens (Bell et al., 1990) .
Furthermore, the median time to clinical CR is less than required for the disappearance of MY-CFUc from their bone marrow (Maitland et al., 1990) or for the detection of the malignant clone by molecular techniques (Bird et al., 1993 Selvanayagam et al., 1988) .
Our data suggest that mutated N-or K-ras alleles are unlikely to be of clinical importance in multiple myeloma as is the case with non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Our ability to culture the tumour in vitro independently of the disease status or prognosis of individual patients suggests that immunoregulatory mechanisms contribute to tumour control in vivo, and genetic changes in some individuals may necessitate the provision of additional growth factors in vitro, as has been reported by other workers (Kawano et al.. 1988) .
